|1.||Von Hoff, Daniel D: 9 articles (11/2015 - 12/2011)|
|2.||Bhar, Paul: 7 articles (04/2013 - 08/2009)|
|3.||Desai, Neil: 7 articles (12/2011 - 05/2008)|
|4.||Socinski, Mark A: 6 articles (03/2015 - 05/2008)|
|5.||Iglesias, Jose: 6 articles (10/2013 - 06/2010)|
|6.||Renschler, Markus F: 5 articles (03/2015 - 06/2012)|
|7.||Glück, Stefan: 5 articles (01/2015 - 09/2010)|
|8.||Gradishar, William J: 5 articles (04/2013 - 06/2006)|
|9.||Trieu, Vuong: 5 articles (12/2011 - 06/2008)|
|10.||Hidalgo, Manuel: 4 articles (11/2015 - 12/2011)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2015 - "Intense regimens of nab-paclitaxel may not be the best treatment approach for unselected patients with metastatic breast cancer, but may suit a subset of patients for whom immediate disease control is required. "
07/01/2007 - "Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy."
01/01/2014 - "Due to these results, to date nab-paclitaxel stands out as a promising treatment of metastatic breast cancer."
10/01/2011 - "Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis."
01/01/2011 - "Recently, several phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer."
01/01/2015 - "Future, larger trials are needed to validate that nab-paclitaxel is beneficial for clinical tumor stage II and the triple-negative subgroup."
10/15/2010 - "HVGGSSV-nab-paclitaxel treatment induced a significantly greater loss in vasculature in irradiated tumors compared with unirradiated tumors, nab-paclitaxel, SGVSGHV-nab-paclitaxel, and untreated controls. "
07/01/2007 - "The superior efficacy of nab-paclitaxel is presumably due to the improved safety profile, which allows for the administration of higher doses, a greater proportion of which actually reaches the tumor. "
11/01/2014 - "Efficacy of nab-paclitaxel in MBC does not seem to be associated with expression of SPARC in tumor tissues or serum."
03/15/2007 - "Nab-paclitaxel showed single-agent antitumor efficacy against both tumor types and acted as a radiosensitizer. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
04/01/2013 - "This study was designed to determine the efficacy of nab-paclitaxel monotherapy in previously treated pancreatic cancer patients. "
04/01/2013 - "A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer."
01/01/2015 - "The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option. "
10/14/2014 - "Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'."
04/01/2014 - "This review discusses the clinical and experimental advances of nab-paclitaxel in pancreatic cancer. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2008 - "We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC). "
11/01/2014 - "nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update."
02/01/2014 - "nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer."
06/01/2015 - "The aim of this clinical study was to evaluate the efficacy and safety of nab-paclitaxel to treat patients with advanced non-small cell lung cancer (NSCLC) who failed first-line chemotherapy. "
06/01/2015 - "A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer."
03/01/2013 - "Nanoparticle albumin-bound (nab)-paclitaxel has been recently approved for the use in breast and NSCLC with very promising results in pancreatic adenocarcinoma. "
12/01/2013 - "Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma."
10/01/2013 - "The superior antitumor activity of nab-paclitaxel provides a strong rationale for considering nab-paclitaxel as first-line monotherapy in pancreatic ductal adenocarcinoma."
04/01/2015 - "Chemotherapy with nab-paclitaxel may be effective for patients with multi-recurrent adenocarcinoma."
04/01/2013 - "The primary objective of this study was to evaluate the dose-limiting toxicities (DLTs) and identify the maximum-tolerated dose (MTD) and recommended dose of nab-paclitaxel plus gemcitabine as a first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma (PDA). "
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)